This chart shows the National Cancer Center Network Guidelines, 2014, for use of the PSA test and Digital Rectal Exam (DRE) for early detection of prostate cancer. Recommendations for men over age 70 are below the chart.
April 23, 2015. For the past twenty years cancer researchers have been worried about the rate of prostate cancer in African-American men. African American men have the highest rates of prostate cancer incidence and mortality in the United States.
Now a large study suggests obesity may play an important role behind what the researchers call the “African-American race effect” on disparities in prostate cancer risk....continue reading Obesity Significantly Increases Prostate Cancer Risk in African-American Men
For cancer patients, a brisk walk or a slow jog on a regular basis may be the key to improved cancer treatments.
Brad Behnke, associate professor of exercise physiology at Kansas State University has shown together with colleagues that moderate exercise on a regular basis enhances tumor oxygenation. Getting more oxygen into a tumor may improve treatments in cancer patients. ...continue reading Moderate Exercise May Make Cancer Treatments More Effective
In mouse models immune cell manipulation plus chemotherapy achieves prostate cancer remission where chemotherapy alone fails
Blocking or removing immune-suppressing cells , researchers at the University of California, San Diego School of Medicine have found, allows a special type of chemotherapy — and the immune cells it activates — to destroy prostate tumors.
This combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of advanced prostate cancer. ...continue reading Targeting B Cells to Tackle Immune System Suppression in High Risk Prostate Cancers
President Obama is proposing "a major new initiative to develop drugs tailored to the genetic characteristics of individual patients, but he expresses deep concern about the costs of such specialty medicines for consumers and for the Medicare program," reports Robert Pear in April 27 New York Times. ...continue reading Obama Proposes That Medicare Be Given the Right to Negotiate the Cost of Drugs
Advocating for advanced prostate cancer patients in Scotland, Alister Walker, Chairman and volunteer in Perth & Kinross Prostate Cancer Support Group, writes in the Scottish newspaper The Herald:
"Last week we read the good news that Moderator-Designate of the General Assembly of the Church of Scotland, the Reverend Dr Angus Morrison, has overcome the disease (Church leader in cancer warning , The Herald, April 23). With prostate cancer so often being symptomless in its early stages he is right to urge other men to consider speaking to their GP about the disease. This is particularly important for men aged over 50, black men and men whose father or brother has had the disease - who are at a higher risk. ...continue reading Abiraterone rejection in Scotland must be overturned, Prostate Cancer advocate says
April 29, 2015. Many patients with higher-risk localized prostate cancer are treated with external beam radiation or with brachytherapy (seed implants). A clinical trial conducted by Dr James Miller (right) of Vancouver, Canada has found that patients receiving permanent implant brachytherapy "seeds" plus a boost of radiation have a better chance of long-term survival than those treated with higher dose-escalated external beam radiotherapy but without the implants.
Men receiving the radioactive "seeds" were more likely to be cancer-free five to nine years later. ...continue reading Brachytherapy combination improves PSA-free survival for patients with higher-risk localized prostate cancer, trial finds
A normal prostate wedges neatly into the crowded multifunctional area of a man's lower pelvis. The prostate in men, like the breast in a woman, is a gland that produces and secretes fluid and controls the fluid's flow.
Implantable device could allow doctors to test cancer drugs in patients before prescribing
PSA Rising-- April 24, 2015, More than 100 drugs have been approved in the USA to treat cancer, but predicting which ones will help an individual patient is an inexact science. Patients may undergo weeks of noxious side effects before scans reveal that for this patient a particular drug is not working--even though it works for the patient in the next chair. A new implantable device, about the size of a grain of rice, may change that. ...continue reading A Step Toward Personalized Chemotherapy